Q4 FY2025 · ended Sep 30, 2025 · Revenue $-91,787, -106.1% YoY · Filed Dec 19, 2025
Outlook Therapeutics, Inc. (OTLK) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $11.2 million in cash and investments and $204,144 in total debt.
Revenue
$-91,787
-106.1% vs prior quarter
Net income
$-20.32M
-0.8% vs year-ago quarter
Operating cash flow
$-21.01M
-76.5% vs year-ago quarter
Free cash flow
—
EPS
$-0.15
+72.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
243.45M
+448.1% vs year-ago quarter
Net cash
$11.04M
Q3 FY2026
Operating margin
18863.9%
Q4 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OTLK (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Iselin, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1649989
- Former names
- Oncobiologics, Inc. (until Nov 13, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q4 FY2025 Sep 30, 2025 |
Q3 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | -$91,787 | $1.5M |
| Operating income | -$10.8M | -$14.0M | -$13.5M | -$17.3M | -$15.7M |
| Net income | -$20.3M | -$4.5M | -$23.1M | -$13.3M | -$20.2M |
| Diluted EPS | -$0.15 | -$0.05 | -$0.38 | -$0.28 | -$0.55 |
| Operating cash flow | -$21.0M | -$7.8M | -$14.9M | -$12.4M | -$11.9M |
| Total assets | $26.2M | $21.9M | $18.2M | $18.6M | $22.4M |
| Total liabilities | $36.6M | $50.9M | $56.8M | $50.8M | $59.6M |
| Stockholders' equity | -$10.4M | -$29.0M | -$38.5M | -$32.2M | -$37.2M |
| Cash and investments | $11.2M | $7.7M | $8.7M | $8.1M | $8.9M |
| Total debt | $204,144 | $218,961 | $233,113 | $247,698 | $260,705 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Sep 30, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 18, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2026 | Aug 23, 2026 |
| 10-Q | Quarterly report | Aug 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
All 833 Outlook Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.